21-Gene Recurrence Score Index (ONCOTYPE DX) as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2-breast cancer

被引：0
|
作者：
Cudos, Ariadna Gasol
Murillo, Serafin Morales
Der-Abrain, Noemi Tuset
Villellas, Felip Vilardell
Cid, Laura Arbones
Olive, Jordi Mele
Morales, Carles Canosa
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-01-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-01-10
引用
收藏
页数：2
相关论文
共 50 条
  • [21] 21-gene recurrence score® in patients with primary metastatic ER+HER2-breast cancer
    Barinoff, J.
    Anastasiadou, L.
    Brandi, C.
    Junker-Stein, A.
    Silbermann, J.
    Langenfeld, M.
    Fortmann, C.
    Thill, M.
    CANCER RESEARCH, 2017, 77
  • [22] The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
    Jegadeesh, Naresh K.
    Kim, Sunjin
    Prabhu, Roshan S.
    Oprea, Gabriela M.
    Yu, David S.
    Godette, Karen G.
    Zelnak, Amelia B.
    Mister, Donna
    Switchenko, Jeffrey M.
    Torres, Mylin A.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1088 - 1094
  • [23] The 21-Gene Recurrence Score and Locoregional Recurrence in Breast Cancer Patients
    Naresh K. Jegadeesh
    Sunjin Kim
    Roshan S. Prabhu
    Gabriela M. Oprea
    David S. Yu
    Karen G. Godette
    Amelia B. Zelnak
    Donna Mister
    Jeffrey M. Switchenko
    Mylin A. Torres
    Annals of Surgical Oncology, 2015, 22 : 1088 - 1094
  • [24] Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
    Guerrero-Zotano, A.
    Perez-Garcia, J. M.
    Ruiz-Borrego, M.
    Bermejo, B.
    Gil-Gil, M.
    de la Haba, J.
    Conejo, E. Alba
    Quiroga, V
    Caranana, V
    Urruticoechea, A.
    Morales, S.
    Bellet, M.
    Anton, A.
    Fernandez-Abad, M.
    Sanchez-Rovira, P.
    Calabuig, L.
    Perez-Escuredo, J.
    Sampayo-Cordero, M.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (10)
  • [25] Outcomes in Premenopausal Patients with HR+/HER2-Breast Cancer and Lymph Node Micrometastasis Based on the 21-Gene Recurrence Score
    Bilani, Nadeem
    Patel, Rima
    Crowley, Fionnuala
    Tiersten, Amy
    ONCOLOGIST, 2023, : 1049 - 1054
  • [26] The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort
    Grenader, Tal
    Yerushalmi, Rinat
    Tokar, Margarita
    Fried, Georgeta
    Kaufman, Bella
    Peretz, Tamar
    Geffen, David B.
    ONCOLOGY, 2014, 87 (01) : 1 - 6
  • [27] Distribution of the 21-gene recurrence score (RS) assay (Oncotype DX) in carriers of germline mutations associated with breast cancer predisposition syndromes
    Giridhar, Karthik V.
    Choong, Grace M.
    Yadav, Siddartha
    Polley, Eric C.
    Leon-Ferre, Roberto A.
    Liu, Minetta C.
    Goetz, Matthew P.
    Couch, Fergus J.
    CANCER RESEARCH, 2020, 80 (04)
  • [28] Oncotype DX Recurrence Score as an Informative Tool to Optimize Neoadjuvant Therapy in HR-positive, HER2negative Breast Cancers
    Luzhna, Lidiya
    Chia, Stephen
    Pauls, Mehrnoosh
    Levasseur, Nathalie
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Oncotype DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma
    Chen, Rui
    Wang, Yun
    Li, Taolang
    Lv, Junyuan
    Feng, Guoli
    Tan, Na
    Wang, Jinjing
    Cheng, Xiaoming
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [30] Influence of a 21-Gene Recurrence Score Assay on Chemotherapy Delivery in Breast Cancer
    Rutter, Charles E.
    Yao, Xiaopan
    Mancini, Brandon R.
    Aminawung, Jenerius A.
    Chagpar, Anees B.
    Saglam, Ozlen
    Hofstatter, Erin W.
    Abu-Khalaf, Maysa
    Gross, Cary P.
    Evans, Suzanne B.
    CLINICAL BREAST CANCER, 2016, 16 (01) : 59 - 62
12345